Anti-Mouse CD309 (FLK1) PE 50 ug
- Known as:
- Antibody toMouse CD309 (FLK1) PE 50 ug
- Catalog number:
- 12-5821-81
- Category:
- -
- Supplier:
- eBioscience
- Gene target:
- Anti-Mouse CD309 (FLK1) 50
Related genes to: Anti-Mouse CD309 (FLK1) PE 50 ug
- Gene:
- KDR NIH gene
- Name:
- kinase insert domain receptor
- Previous symbol:
- -
- Synonyms:
- FLK1, VEGFR, VEGFR2, CD309
- Chromosome:
- 4q12
- Locus Type:
- gene with protein product
- Date approved:
- 1991-07-10
- Date modifiied:
- 2019-04-23
Related products to: Anti-Mouse CD309 (FLK1) PE 50 ug
Related articles to: Anti-Mouse CD309 (FLK1) PE 50 ug
- Conventional chemotherapeutic treatment of colorectal cancer causes adverse effects such as severe diarrhoea, mucositis and hepatotoxicity. This study aimed to investigate the anti-carcinogenic potential of epigallocatechin-3-gallate and its effects on major angiogenic markers, alone and in combination with irinotecan in colorectal cancer model. - Source: PubMed
Publication date: 2026/09/17
Rahman Sabana SargamBaruah SukanyaAkhtara NabilaNath Jaydeep KumarBharali Manuj Kumar - - Source: PubMed
Publication date: 2026/09/16
Wang YuhengWei XiaoluWang HuijunZhang YanLi PengyueZhou YawenJiang ShanRong YanChen LihuaZhao Haiyu - Vascular endothelial growth factor receptor-2 (VEGFR-2) is a vital mediator of angiogenesis. Therefore, VEGFR-2 inhibition is considered a promising therapeutic target to combat cancer. In the present study, a series of 22 imidazo[4,5-b]pyridine-acrylonitrile-based derivatives was designed and synthesized. All compounds were evaluated for their VEGFR-2 inhibitory activity. Seven of the tested compounds showed high inhibitory activity against VEGFR-2 with IC (0.029-0.087 µM) compared to reference drug sorafenib IC = 0.091 µM. Four of these derivatives were selected for in vitro cytotoxic activity against breast cancer (MCF-7) and hepatocellular (HepG2) carcinoma cell lines, showing IC (0.073-0.196 µM) and (0.20-0.21 µM), respectively, relative to sorafenib IC 0.16 and 0.19 µM, respectively. Compound 2f exhibiting a superior VEGFR-2 inhibition (IC = 0.029 µM compared to sorafenib IC = 0.091 µM) and cytotoxicity against MCF-7 and HepG2 (IC = 0.073 µM and IC = 0.09 µM, respectively), was subjected to cell cycle analysis, apoptosis assay, and molecular modeling studies, which strongly supported the results. It caused cell cycle arrest at G2/M phase by 13.67% and a promising apoptosis induction. 2f exhibited a promising binding score and pose inside the VEGFR-2 active sites. It also showed a good safety profile with a moderate selectivity index. Based on the prediction of physicochemical and pharmacokinetic properties for 2f, it showed excellent prediction results to be orally bioavailable. - Source: PubMed
Mohamed Lamia WSaadeldin Ahmed AFarag Ayman B - Clear cell odontogenic carcinoma (CCOC) and hyalinizing clear cell carcinoma (HCCC), rare head-and-neck malignancies with recurrent EWSR1::CREB family fusions, show overlapping morphologic and immunophenotypic features; no standardized systemic therapy for either exists. Given tissue constraints, the molecular relationship of CCOC and HCCC to each other and to relevant head-and-neck cancers remains incompletely defined. We used spatial transcriptomic profiling, multiplex immunofluorescence (mIF), and RNA in situ hybridization (RNA-ISH) to characterize the molecular and immune landscape of CCOC, HCCC, and relevant head-and-neck and fusion-associated comparators. Key transcriptomic findings were validated by RNA-ISH (image-based signal quantification), complemented by mIF-defined immune-cell composition, antigen-presentation features, and architecture. CCOC and HCCC demonstrated highly overlapping transcriptomic profiles; clear cell sarcoma, despite shared EWSR1::CREB family fusion contexts, remained distinct. CCOC and HCCC showed enrichment of a shared epithelial-secretory program, with ductal, luminal, and regulated secretory pathway features. IGF2, among the most enriched shared transcripts, showed strong tumor-cell associated expression. Candidate targets included: TACSTD2 (TROP2), FGFR2, FOLR1, KDR, MSLN, and MUC1. mIF profiling demonstrated low B2M and HLA-I expression, sparse lymphoid infiltration, minimal PD-L1 expression, and an overall immune-cold phenotype, consistent with impaired antigen presentation. Transcriptome-wide evidence showed CCOC and HCCC share a common molecular identity, particularly distinct from myoepithelial carcinoma and squamous cell carcinoma. Implications: This study - the most comprehensive molecular comparison to date of CCOC and HCCC, set against each other and relevant differential diagnoses - establishes a shared molecular framework that may improve diagnostic classification and guide biomarker and therapeutic development for these exceptionally rare tumors. - Source: PubMed
Publication date: 2026/09/15
Hou Helen XLi AnniePatel Bidish KAckerman Emily EBisson TomFlynn SamanthaSingh SamyuktaAhmed Afrah MDeol NavkiranRivera CamronKudo YasuseiBertolus ChloeSubarnbhesaj AjiravudhVillanueva AntonioRubio KarlaRichieri Peter MBar-Peled LironTing David TFaquin William CTroulis Maria JRivera Miguel NIafrate A John - Progressive pulmonary fibrosis (PPF) comprises interstitial lung diseases characterized by progressive fibrosis and lung function decline. Nintedanib slows disease progression by inhibiting FGFR, VEGFR, and PDGFR signaling, but treatment response varies among patients. We investigated whether , , and gene variants are associated with nintedanib treatment outcomes, including changes in pulmonary function, diffusing capacity and adverse effects. This prospective study included 75 patients with PPF diagnosed according to ATS/ERS/JRS/ALAT criteria and treated with nintedanib at the Clinic of Pulmonology, University Clinical Center of Serbia. Spirometry and diffusing capacity were assessed at baseline and after 6 and 12 months. Genotyping of rs2071559 and rs1870377; rs2302273, rs2229562, and rs246395; and rs1800470 was performed using TaqMan assays. Carriers of the rs2302273 A allele more frequently experienced gastrointestinal adverse events (45.2% vs. 20.5%; = 0.022; OR 3.2, 95% CI 1.156-8.866) and diarrhea (38.7% vs. 15.9%; = 0.026; OR 3.3, 95% CI 1.129-9.869). Patients with the rs246395 TT genotype more frequently had a ≥15% decline in DLCO after one year (46% vs. 22%; = 0.038; OR 3.0, 95% CI 1.045-8.394). No significant associations were observed for the analyzed or variants. These findings suggest that variants may be associated with nintedanib treatment outcomes, although confirmation in larger cohorts is needed. - Source: PubMed
Publication date: 2026/08/23
Djurdjevic NatasaPjevic Marija DusanovićStjepanovic MihailoColic NikolaDimic-Janjic SanjaJankovic JelenaMaric NikolaZecevic AndrejTerzic MilicaGolubovic AleksaMilivojevic IvanOmcikus MajaIlic BranislavLukic KatarinaMijatovic SnjezanaGrk Milka